Steven Cohen’s SAC Capital Advisors Boosts Its Stake in DeVry Education Group Inc (DV)

Steven Cohen’s SAC Capital Advisors, has significantly increased its position in DeVry Education Group Inc (NYSE:DV) to over 3.17 million shares from 27,391 shares, held at the end of the fourth quarter of 2013. The current holding amasses 5.0% stake of the company’s common stock.

SAC CAPITAL ADVISORS

Recently, DeVry Education Group Inc (NYSE:DV) announced its financial results for the second quarter of 2014, posting a decrease in revenue by 1.9% on the year, to $491.3 million. Net income also fell to $48.2 million, from $50.3 million in the second quarter of 2013. The diluted earnings per share were down at $0.74 from $0.78 last year, and lower than the mean estimates of $0.75.

The company generated $131.1 million of operating cash flow and the cash and cash equivalent decreased by 21% to $262.0 million. There was an increase in the segment revenue to $190.4 million, representing a 13.5% increase over the second quarter of 2013.

Of the other funds we track, Charles De Vaulx’s International Value Advisers, is the largest shareholder of DeVry Education Group Inc (NYSE:DV), which held 4.85 million shares, worth $172.01 million at the end of the fourth quarter. Ariel Investments, managed by John W. Rogers is another fund, which held 2.81 million shares with a reported value of $99.58 million.

Recently, SAC Capital Advisors upped its stake in Lumber Liquidators Holdings Inc (NYSE:LL) to 1.39 million shares, from 60,144 shares held previously. Last month, Steven Cohen initiated a position in Retrophin Inc (NASDAQ:RTRX), which amasses 1.29 million shares of the company.

Disclosure: none

Recommended Reading:

Corvex Capital Exercises Options and Reiterates Stake in Signet Jewelers Limited (SIG)

Carl Wiese’s Grow Partners Top Picks in Q4

York Capital Management’s Top Q4 Holdings

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!